Intravenous immunoglobulin for myasthenia gravis

重症肌无力 医学 安慰剂 恶化 神经肌肉疾病 内科学 临床试验 抗体 自身抗体 随机对照试验 自身免疫性疾病 儿科 疾病 免疫学 替代医学 病理
作者
Philippe Gajdos,Sylvie Chevret,Klaus V. Toyka
出处
期刊:The Cochrane library [Wiley]
被引量:275
标识
DOI:10.1002/14651858.cd002277.pub4
摘要

Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007.To examine the efficacy of IVIg for treating exacerbations of myasthenia gravis or for chronic myasthenia gravis.We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 October 2011), CENTRAL (2011, Issue 3), MEDLINE (January 1966 to September 2011) and EMBASE (January 1980 to September 2011) using 'myasthenia gravis' and 'intravenous immunoglobulin' as the search terms.All randomised controlled trials (RCTs) or quasi-RCTs in which IVIg was compared with no treatment, placebo or plasma exchange, in people with myasthenia gravis.One review author extracted the data and two others checked these data. For methodological reasons, no formal meta-analysis was performed.We identified seven RCTs. These trials differ in inclusion criteria, comparison with alternative treatment and outcomes. In a trial comparing IVIg with placebo, including 51 participants with myasthenia gravis worsening, the mean difference (MD) in quantitative myasthenia gravis score (QMGS) (MD 95% CI) after 14 days was: -1.60 (95% CI - 3.23 to 0.03) this result being borderline statistically significant in favour of IVIg. In an unblinded study of 87 participants with exacerbation comparing IVIg and plasma exchange there was no difference in myasthenic muscle score (MMS) after 15 days (MD -1.00; 95% CI -7.72 to 5.72). In a study of 84 participants with worsening myasthenia gravis there was no difference in change in QMGS 14 days after IVIg or plasma exchange (MD -1.50; 95% CI -3.43 to 0.43). In a study of 12 participants with moderate or severe myasthenia gravis, which was at high risk of bias from skewed allocation, the mean fall in QMGS both for IVIg and plasma exchange after four weeks was significant (P < 0.05). A study with 15 participants with mild or moderate myasthenia gravis found no difference in change in QMGS 42 days after IVIg or placebo (MD 1.60; 95% CI -1.92 to 5.12). A study included 33 participants with moderate exacerbations of myasthenia gravis and showed no difference in change in QMGS 14 days after IVIg or methylprednisolone (MD -0.42; 95% CI -1.20 to 0.36). All these three smaller studies were underpowered. The last trial, including 168 people with exacerbations, showed no evidence of superiority of IVIg 2 g/kg over IVIg 1 g/kg on the change of MMS after 15 days (MD 3.84; 95% CI -0.98 to 8.66). Adverse events due to IVIg were moderate (fever, nausea, headache), self-limiting and subjectively less severe than with plasma exchange (although, given the available data, no statistical comparison was possible). Other than where specific limitations are mentioned the trials were generally at low risk of bias.In exacerbation of myasthenia gravis, one RCT of IVIg versus placebo showed some evidence of the efficacy of IVIg and two did not show a significant difference between IVIg and plasma exchange. Another showed no significant difference in efficacy between 1 g/kg and 2 g/kg of IVIg. A further, but underpowered, trial showed no significant difference between IVIg and oral methylprednisolone. In chronic myasthenia gravis, there is insufficient evidence from RCTs to determine whether IVIg is efficacious.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin的应助被应万言采纳,获得10
1秒前
1秒前
苏苏828完成签到,获得积分10
1秒前
不真完成签到,获得积分10
2秒前
寒冷紫青的应助被Fun_112采纳,获得30
2秒前
GXL发布了新的文献求助10
2秒前
2秒前
2秒前
Jerry发布了新的文献求助10
2秒前
FashionBoy的应助被qqqqqqqqqq采纳,获得10
3秒前
3秒前
你好发布了新的文献求助10
3秒前
Maria完成签到 ,获得积分10
3秒前
小蘑菇的应助被乐爱来采纳,获得10
3秒前
4秒前
粗犷的海冬完成签到,获得积分10
4秒前
4秒前
6秒前
6秒前
TirionFecup完成签到,获得积分10
6秒前
苏苏828发布了新的文献求助10
6秒前
ll完成签到,获得积分10
6秒前
斯文败类的应助被zenghong采纳,获得10
7秒前
hw完成签到,获得积分10
7秒前
7秒前
hexy629发布了新的文献求助10
7秒前
yyds的应助被Fun_112采纳,获得30
7秒前
lu完成签到 ,获得积分10
7秒前
seet完成签到 ,获得积分10
8秒前
8秒前
zhang完成签到,获得积分10
8秒前
苦瓜发布了新的文献求助30
8秒前
8秒前
小马甲的应助被小祝没吃饱采纳,获得10
9秒前
打打的应助被sasakiki采纳,获得10
10秒前
10秒前
喜悦南风发布了新的文献求助20
11秒前
llllll发布了新的文献求助10
11秒前
12秒前
rjx发布了新的文献求助20
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194174
求助须知:如何正确求助?哪些是违规求助? 9580103
关于积分的说明 21869209
捐赠科研通 7793764
什么是DOI,文献DOI怎么找? 3437545
关于科研通互助平台的介绍 2560983
邀请新用户注册赠送积分活动 2484291